Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit from treatment with these agents. In addition, the faculty will discuss individualizing treatment using S1P receptor modulators for appropriate patients with IBD in accordance with current evidence and guidelines. Upon completion of this activity, participants should be better able to: Explain how the therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators address the underlying pathophysiology of IBD; Identify patients with UC who could benefit from the use of therapy with S1P receptor modulators; and Individualize treatment using S1P receptor modulators for appropriate patients with UC in accordance with current evidence and guidelines
View all episodes
